We are live on ! Find out more
DM

Deerfield Management Portfolio holdings

AUM $8.48B
1-Year Est. Return 99.04%
This Fund
S&P 500
This Quarter Est. Return
+15.28%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$2.15B
AUM Growth
-$394M
Cap. Flow
-$894M
Cap. Flow %
-41.57%
Top 10 Hldgs %
42.88%
Holding
116
New
14
Increased
12
Reduced
29
Closed
26

Top Buys

Rank Stock Value
1
NVRO
NEVRO CORP.
NVRO
+$48.4M
2
PTLA
Portola Pharmaceuticals, Inc.
PTLA
+$46.1M
3
TSRO
TESARO, Inc.
TSRO
+$22.6M
4
BOLD
Audentes Therapeutics, Inc
BOLD
+$21.3M
5
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$17.6M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$143M
2
XNPT
XENOPORT, INC.
XNPT
+$81.5M
3
TVTY
Tivity Health, Inc. Common Stock
TVTY
+$49.8M
4
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
+$35.4M
5
VNDA icon
Vanda Pharmaceuticals
VNDA
+$34.5M

Sector Composition

Rank Sector Weight
1 Healthcare 70.12%
2 Financials 3.34%
3 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EPIX
51
DELISTED
ESSA Pharma
EPIX
$5.83M 0.27%
106,080
-1,778
-2% -$95K
OPCH icon
52
Option Care Health
OPCH
$3.41B
$5.7M 0.27%
492,807
-253,893
-34% -$2.74M
CASM
53
DELISTED
CAS Medical Systems, Inc.
CASM
$5.53M 0.26%
3,200,000
– –
ZVRA icon
54
Zevra Therapeutics
ZVRA
$755M
$4.87M 0.23%
67,778
-21,003
-24% -$1.49M
NSTG
55
DELISTED
NanoString Technologies, Inc.
NSTG
$4.53M 0.21%
226,691
-447,931
-66% -$7.11M
EYPT icon
56
EyePoint Inc
EYPT
$1.12B
$4.49M 0.21%
149,282
– –
ATXS
57
DELISTED
Astria Therapeutics
ATXS
$4.21M 0.2%
11,390
+664
+6% +$175K
SCYX icon
58
SCYNEXIS
SCYX
$42.4M
$4.06M 0.19%
13,100
-9,065
-41% -$1.91M
GBT
59
DELISTED
Global Blood Therapeutics, Inc.
GBT
$3.95M 0.18%
171,428
-1,562,400
-90% -$29.8M
GNCA
60
DELISTED
Genocea Biosciences, Inc.
GNCA
$3.52M 0.16%
85,907
– –
ACOR
61
DELISTED
Acorda Therapeutics
ACOR
$3.37M 0.16%
1,346
-7,232
-84% -$21.6M
EXEL icon
62
Exelixis
EXEL
$14.1B
$3.16M 0.15%
+246,907
New +$2.67M
INFI
63
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
$3.02M 0.14%
1,935,942
– –
ACRS icon
64
Aclaris Therapeutics
ACRS
$793M
$2.97M 0.14%
+116,000
New +$2.46M
KA
65
DELISTED
Kineta, Inc. Common Stock
KA
$2.9M 0.13%
+1,329
New +$2.47M
EPZM
66
DELISTED
Epizyme, Inc
EPZM
$2.87M 0.13%
291,179
-331,120
-53% -$3.02M
VYGR icon
67
Voyager Therapeutics
VYGR
$192M
$2.83M 0.13%
235,294
– –
TRIL
68
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.55M 0.12%
172,307
– –
SRRA
69
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$2.52M 0.12%
34,678
-5,540
-14% -$428K
RAD
70
DELISTED
Rite Aid Corporation
RAD
$2.12M 0.1%
13,750
-116,829
-89% -$17.4M
TVTY
71
DELISTED
Tivity Health, Inc. Common Stock
TVTY
$2.01M 0.09%
76,000
-2,465,686
-97% -$49.8M
AGRX
72
DELISTED
Agile Therapeutics
AGRX
$1.75M 0.08%
125
– –
ACUR
73
DELISTED
Acura Pharmaceuticals
ACUR
$1.64M 0.08%
1,025,641
– –
OCRX
74
DELISTED
Ocera Therapeutics, Inc.
OCRX
$1.51M 0.07%
572,893
– –
NEOS
75
DELISTED
Neos Therapeutics, Inc
NEOS
$1.51M 0.07%
229,166
-229,166
-50% -$1.82M
1 2
3
4 5

Similar funds

FT
Fiduciary Trust Boston, Massachusetts $8.46B AUM 21.38% 1-Year Est. Return
GRQ
Gardner Russo & Quinn Lancaster, Pennsylvania $8.5B AUM 9.79% 1-Year Est. Return
AV
ASR Vermogensbeheer Utrecht, Netherlands $8.5B AUM 25.14% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $8.52B AUM 37.76% 1-Year Est. Return
VA
Valmark Advisers Akron, Ohio $8.42B AUM 14.36% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $8.4B AUM 63.34% 1-Year Est. Return
IC
Icahn Carl Sunny Isles Beach, Florida $8.55B AUM 29.29% 1-Year Est. Return
NW
NewEdge Wealth Pittsburgh, Pennsylvania $8.39B AUM 24.47% 1-Year Est. Return

Deerfield Management's Q3 2016 Portfolio in Review

As of Q3 2016, Deerfield Management held 116 positions worth $2.15B, down 15% from $2.54B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Deerfield Management withdrew a net $894M in Q3 2016, closing 26 positions and reducing 29 holdings. Its most notable exit was XENOPORT, INC., an estimated $81.5M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, up from 69% a quarter earlier, followed by Financials and Industrials.

Against the trend, Deerfield Management opened a new position in NEVRO CORP. worth $56M.

  • Deerfield Management's largest Q3 2016 buy was NEVRO CORP.: 536,355 shares worth $56M.
  • Deerfield Management added most to Portola Pharmaceuticals, Inc. in Q3 2016, an estimated $46.1M increase.
  • Deerfield Management's biggest Q3 2016 reduction was Horizon Therapeutics Public Limited Company Ordinary Shares, cutting an estimated $143M.
  • Deerfield Management fully exited XENOPORT, INC. in Q3 2016, selling an estimated $81.5M.
  • Deerfield Management's ten largest holdings make up 43% of its $2.15B portfolio in Q3 2016.
  • Deerfield Management opened 14 new positions and closed 26 in Q3 2016.
  • Deerfield Management's portfolio value fell 15% quarter-over-quarter to $2.15B.

Based on Deerfield Management's 13F filing for Q3 2016, filed 14 Nov 2016.